Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 1/20 | 0.33 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 2/20 | 0.32 |
| ▸ | RXRB | P28702 | 2/20 | 0.32 |
| ▸ | RXRG | P48443 | 2/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.32 |
| ▸ | PPARG | P37231 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7177789 | 0.89 | AKR1C3 (0.33) | RXRARXRBRXRGPPARGKMT2A | |
| SCHEMBL7188855 | 0.88 | FFAR1 (0.33) | KCNK3KCNK9RXRARXRBRXRG | |
| SCHEMBL7735853 | 0.85 | RXRA (0.33) | KCNK3KCNK9RXRARXRBRXRG | |
| SCHEMBL7178289 | 0.84 | NLRP3 (0.31) | PPARGKDM4E | |
| SCHEMBL7190017 | 0.84 | FFAR1 (0.35) | FFAR1PPARG | |
| SCHEMBL7187115 | 0.84 | RXRA (0.40) | KCNK3KCNK9RXRARXRBRXRG | |
| SCHEMBL7181435 | 0.84 | FFAR1 (0.35) | FFAR1PPARGKDM4EKMT2AEPHX2 | |
| SCHEMBL7189987 | 0.84 | SMN1; SMN2 (0.36) | KMT2A | |
| Lithium SCHEMBL7188242 | 0.80 | PPARD (0.34) | FFAR1PPARGKDM4EKMT2AEPHX2 | |
| SCHEMBL7175436 | 0.80 | FFAR1 (0.35) | FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6579663-B2 | Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides | CIBA SPECIALTY CHEMICALS CORPORATION | 2003-06-17 | — | — | US | disclosed |
| US-20020107413-A1 | Organometallic monoacylarylphosphines | WOLF JEAN-PIERRE (CH) | 2002-08-08 | — | — | US | disclosed |
| US-6399805-B2 | SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES | CIBA SPECIALTY CHEMICALS CORPORATION | 2002-06-04 | — | — | US | disclosed |
| US-20010031898-A1 | Organometallic monoacylarylphosphines | CIBA SPECIALTY CHEMICALS CORP. | 2001-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107413-A1 | Organometallic monoacylarylphosphines | CBR1, NAF1, DHCR24 | KCNK3 351/4885KCNK9 352/4885RXRA 2745/4885 |
| US-20010031898-A1 | Organometallic monoacylarylphosphines | NAF1, DHCR24, CBR1 | KCNK3 388/4885KCNK9 553/4885RXRA 2809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.